-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99

Benzinga·07/29/2026 16:53:38
Listen to the news
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $72 to $99.